Inicio / Reumatología / Abstracts de reumatología / A roadmap to target interleuk…

A roadmap to target interleukin-6 in osteoarthritis

0 / 5 (0 votos)
A roadmap to target interleukin-6 in osteoarthritis

Rheumatology Oxford Journal

Fecha de publicación: 21 July 2020


Autores: Renske Wiegertjes, Fons A J van de Loo, Esmeralda N Blaney Davidson

Background: Joint inflammation is present in the majority of OA patients and pro-inflammatory mediators, such as IL-6, are actively involved in disease progression. Increased levels of IL-6 in serum or synovial fluid from OA patients correlate with disease incidence and severity, with IL-6 playing a pivotal role in the development of cartilage pathology, e.g. via induction of matrix-degrading enzymes. However, IL-6 also increases expression of anti-catabolic factors, suggesting a protective role. Until now, this dual role of IL-6 is incompletely understood and may be caused by differential effects of IL-6 classic vs trans-signalling. Here, we review current evidence regarding the role of IL-6 classic- and trans-signalling in local joint pathology of cartilage, synovium and bone. Furthermore, we discuss targeting of IL-6 in experimental OA models and provide future perspective for OA treatment by evaluating currently available IL-6 targeting strategies.

Leer más


Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.